MX2017016423A - Polvos de zolmitriptán para sumunistro pulmonar. - Google Patents

Polvos de zolmitriptán para sumunistro pulmonar.

Info

Publication number
MX2017016423A
MX2017016423A MX2017016423A MX2017016423A MX2017016423A MX 2017016423 A MX2017016423 A MX 2017016423A MX 2017016423 A MX2017016423 A MX 2017016423A MX 2017016423 A MX2017016423 A MX 2017016423A MX 2017016423 A MX2017016423 A MX 2017016423A
Authority
MX
Mexico
Prior art keywords
triptan
powders
pulmonary delivery
disease
spray
Prior art date
Application number
MX2017016423A
Other languages
English (en)
Inventor
M Lipp Michael
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MX2017016423A publication Critical patent/MX2017016423A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

La invención proporciona formulaciones de partícula estable, secadas por aspersión que contienen un triptán, preferentemente sumatriptán, o una sal farmacéuticamente aceptable de este, útiles para administración pulmonar en el tracto respiratorio de un paciente para tratar una enfermedad.
MX2017016423A 2015-07-02 2016-07-01 Polvos de zolmitriptán para sumunistro pulmonar. MX2017016423A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188338P 2015-07-02 2015-07-02
PCT/US2016/040660 WO2017004501A1 (en) 2015-07-02 2016-07-01 Triptan powders for pulmonary delivery

Publications (1)

Publication Number Publication Date
MX2017016423A true MX2017016423A (es) 2018-12-11

Family

ID=57609192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016423A MX2017016423A (es) 2015-07-02 2016-07-01 Polvos de zolmitriptán para sumunistro pulmonar.

Country Status (9)

Country Link
US (2) US10034857B2 (es)
EP (1) EP3316865A4 (es)
JP (1) JP2018524346A (es)
KR (1) KR20180052566A (es)
AU (1) AU2016287582B2 (es)
CA (1) CA2991108A1 (es)
HK (1) HK1254670A1 (es)
MX (1) MX2017016423A (es)
WO (1) WO2017004501A1 (es)

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW19381A1 (en) 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
GB9101592D0 (en) 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
NZ337065A (en) 1997-02-05 2001-02-23 Jago Pharma Ag Medical aerosol formulations containing carbon dioxide, a hydrofluoroalkane, a cosolvent and a beta-mimetic / corticoid / anticholinergic / spasmolytic / analgesic agent
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US20060172017A1 (en) 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
ES2303527T3 (es) 2000-05-10 2008-08-16 Jagotec Ag Procedimiento de molienda.
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
ES2415654T3 (es) 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
HUE031167T2 (hu) 2002-03-20 2017-07-28 Civitas Therapeutics Inc A levodopa pulmonális bejuttatása
WO2003079885A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
AU2002334929C1 (en) 2002-03-20 2006-09-14 Advanced Inhalation Research, Inc. Puncturing means for use in an inhalation device
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
MXPA04010990A (es) 2002-05-07 2005-02-14 Nektar Therapeutics Capsulas para inhaladores de polvo seco y metodo s para elaborarlas y utilizarlas.
AU2003280102B2 (en) 2002-06-28 2007-01-25 Alkermes, Inc. Inhalable epinephrine
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
CN1176649C (zh) 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
AU2004212976A1 (en) 2003-02-19 2004-09-02 Biovail Laboratories Inc. Rapid absorption selective 5-HT agonist formulations
ES2872350T3 (es) 2003-06-13 2021-11-02 Civitas Therapeutics Inc Polvos farmacéuticos de dosis baja para inhalación
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060120962A1 (en) 2004-10-12 2006-06-08 Rabinowitz Joshua D Cardiac safe, rapid medication delivery
MX2007009635A (es) 2005-02-10 2007-09-25 Orexo Ab Nuevas composiciones farmaceuticas utiles en la administracion transmucosa de farmacos.
US20090232898A1 (en) 2005-03-28 2009-09-17 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Migraine
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
CA2631493A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
GB0602897D0 (en) 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
WO2008080170A1 (en) 2006-12-22 2008-07-03 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositiions
EP2116264B1 (en) 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US8496002B2 (en) 2007-06-12 2013-07-30 Civitas Therapeutics, Inc. Powder inhaler devices
US8614255B2 (en) 2007-08-21 2013-12-24 Civitas Therapeutics, Inc. Pulmonary pharmaceutical formulations
EP2201003A1 (en) 2007-10-03 2010-06-30 Generics Ýuk¨Limited Process for the preparation of zolmitriptan, salts and solvates thereof
CA2705422A1 (en) 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
CA2728808A1 (en) 2008-02-01 2009-08-06 Vectura Limited Pulmonary formulations of triptans
EP2242526A4 (en) 2008-02-15 2014-06-18 Timothy Sean Immel AEROSOL TREATMENT DEVICE WITH HIGH FREQUENCY ADMINISTRATION
WO2009114192A2 (en) 2008-03-14 2009-09-17 Cephalon, Inc. Enhanced transmucosal composition and dosage form
CN102014625A (zh) 2008-04-28 2011-04-13 佐吉尼克斯股份有限公司 用于治疗偏头痛的新制剂
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
KR101931392B1 (ko) 2010-11-09 2018-12-20 맨카인드 코포레이션 세로토닌 수용체 작용제 및 디케토피페라진을 포함하는 편두통 치료용 조성물
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
US10549052B2 (en) 2012-02-28 2020-02-04 Sipnose Ltd. Nasal delivery device
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
US20150290135A1 (en) 2012-11-16 2015-10-15 Merck Sharp & Dohme Corp. Process for making agglomerates using acoustic mixing technology
WO2016179026A1 (en) * 2015-05-01 2016-11-10 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery

Also Published As

Publication number Publication date
WO2017004501A1 (en) 2017-01-05
US10034857B2 (en) 2018-07-31
CA2991108A1 (en) 2017-01-05
US20200276160A1 (en) 2020-09-03
AU2016287582B2 (en) 2020-03-12
AU2016287582A1 (en) 2017-12-21
HK1254670A1 (zh) 2019-07-26
US20170000765A1 (en) 2017-01-05
EP3316865A4 (en) 2019-01-23
EP3316865A1 (en) 2018-05-09
KR20180052566A (ko) 2018-05-18
JP2018524346A (ja) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
MX2017013950A (es) Polvos de zolmitriptán para suministro pulmonar.
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
MX2017016802A (es) Formulaciones farmaceuticas.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MY186229A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
PH12018500544A1 (en) Inhalable nicotine formulations, and methods of making and using thereof
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
CL2017001859A1 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol
PH12015500823A1 (en) Modified release formulations for oprozomib
HUE044731T2 (hu) Formulációk a száj, torok és respiratorikus traktus rendellenességeinek kezelésére
MY182008A (en) Pharmaceutical formulations
MX2017016423A (es) Polvos de zolmitriptán para sumunistro pulmonar.
MX2020006900A (es) Composición de ketamina en polvo seco para usarse en el tratamiento de depresión por medio de administración pulmonar.
PH12016502527A1 (en) Stabilized desmopressin
MX2017004633A (es) Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas.
NZ740722A (en) Oral suspension for treating eosinophilic esophagitis
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
IN2015MU02542A (es)
MX2014008984A (es) Proceso de obtencion y composicion farmaceutica de fenofibrato capsulas como agente regulador de lipidos para su administracion oral.